Sleep Biomarkers for CBS and PSP

Introduction

Sleep disturbances are among the earliest and most common non-motor symptoms in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), often predating the classic motor syndrome by years. These 4-repeat tauopathies affect brainstem and subcortical structures critical for sleep-wake regulation, producing distinctive sleep biomarker signatures that can aid in differential diagnosis from synucleinopathies like Parkinson's disease and multiple system atrophy["@arnulf2024"].

Introduction

Sleep disturbances are among the earliest and most common non-motor symptoms in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), often predating the classic motor syndrome by years. These 4-repeat tauopathies affect brainstem and subcortical structures critical for sleep-wake regulation, producing distinctive sleep biomarker signatures that can aid in differential diagnosis from synucleinopathies like Parkinson's disease and multiple system atrophy["@arnulf2024"].

This page provides comprehensive coverage of sleep-based biomarkers for CBS and PSP, including circadian rhythm markers, polysomnographic parameters, CSF and blood sleep-related molecules, and actigraphy-derived metrics. These biomarkers serve dual purposes: early detection of neurodegeneration and differentiation from mimics (particularly other atypical parkinsonian syndromes)[@boe2024].

Pathophysiology of Sleep Disorders in CBS/PSP

Brainstem Structures Affected

Both CBS and PSP target brainstem nuclei involved in sleep regulation:

| Structure | Function | Effect of Tauopathy |
|-----------|----------|---------------------|
| Pedunculopontine Nucleus (PPN) | REM sleep generation, arousal | Reduced REM sleep, fragmented sleep |
| Substantia Nigra pars reticulata | Sleep-wake transitions | Sleep fragmentation, insomnia |
| Locus Coeruleus | Noradrenergic arousal, REM atonia | REM behavior disorder, fragmented sleep |
| Dorsal Raphe Nuclei | Serotonergic sleep modulation | Altered sleep architecture |
| Sublaterodorsal Nucleus | REM sleep atonia control | REM without atonia |

CBS vs PSP Sleep Pathology

While both are 4R-tauopathies with sleep dysfunction, important distinctions exist[@schneberger2023]:

| Sleep Parameter | CBS | PSP | Differential Value |
|-----------------|-----|-----|---------------------|
| REM Sleep Behavior Disorder | 0-8% | 0-13% | Low (both rare vs synucleinopathies) |
| Periodic Limb Movements | 50-70% | 60-80% | Moderate |
| Sleep Efficiency | 60-75% | 50-65% | High (PSP more severe) |
| Slow-Wave Sleep | Moderately reduced | Severely reduced | High |
| REM Sleep Percentage | Normal to slightly reduced | Significantly reduced | High |
| Sleep Latency | Normal | Prolonged | Moderate |
| Total Sleep Time | 4-5 hours | 3-4 hours | High |

Circadian Rhythm Biomarkers

Melatonin

Melatonin secretion reflects circadian pacemaker function. In CBS/PSP[@luz2023]:

• Dim light melatonin onset (DLMO) — delayed in 40-60% of CBS/PSP patients
• Melatonin amplitude — reduced in PSP more than CBS
• 6-sulfatoxymelatonin — urinary metabolite shows altered excretion patterns

• Differentiates PSP from PD (more severe reduction in PSP)
• Predicts falls (low melatonin correlates with nocturnal falls)
• Treatment target (melatonin supplementation improves sleep efficiency)

Cortisol

Cortisol rhythm disruption reflects hypothalamic-pituitary-adrenal axis involvement:

| Parameter | CBS | PSP | Control |
|-----------|-----|-----|---------|
| Cortisol awakening response | Reduced | Markedly reduced | Normal |
| Evening cortisol | Normal | Elevated | Normal |
| Cortisol decline ratio | Normal | Reduced | Normal |

Differential Value:

• PSP shows more pronounced cortisol dysregulation than CBS
• Elevated evening cortisol predicts faster disease progression
• May differentiate from AD (AD shows flatter rhythm, not elevated evening)

Core Body Temperature

Ambulatory temperature monitoring reveals:

• Reduced amplitude — 0.3-0.5°C lower than healthy controls
• Phase delay — peak temperature shifted 1-2 hours later
• Increased night-time temperature — loss of nocturnal dip

Polysomnographic Biomarkers

REM Sleep Parameters

REM Sleep Without Atonia (RSWA)

RSWA is the electrophysiological hallmark of REM behavior disorder[@clignet2023]:

| Metric | CBS | PSP | Interpretation |
|--------|-----|-----|----------------|
| Phasic EMG activity | 15-30% | 20-40% | Higher in PSP |
| Tonic chin EMG | Elevated | Markedly elevated | Both show loss of atonia |
| SWEM score | 10-15 | 15-25 | Quantifies RSWA severity |

Key Insight: RSWA is less common in CBS/PSP (<15%) than in synucleinopathies (70-90%), making its presence supportive of CBS/PSP diagnosis.

REM Density and Latency

• REM latency — prolonged in PSP (90-120 min vs 60-80 min in controls)
• REM density — reduced in both CBS and PSP
• REM cycles — fewer cycles (2-3 vs 4-5 in controls)

Sleep Architecture

Polysomnographic Metrics[@arnulf2024]

| Parameter | CBS | PSP | Healthy Control | Pathological Threshold |
|-----------|-----|-----|------------------|------------------------|
| Total Sleep Time | 240-300 min | 180-240 min | 360-420 min | <300 min |
| Sleep Efficiency | 60-75% | 50-65% | >85% | <70% |
| N1 Percentage | 15-25% | 20-35% | 5-10% | >20% |
| N2 Percentage | 45-55% | 40-50% | 45-55% | Variable |
| N3 Percentage | 10-15% | 5-10% | 15-20% | <10% |
| REM Percentage | 15-20% | 10-15% | 20-25% | <15% |
| WASO | 90-120 min | 120-180 min | 30-45 min | >90 min |

Periodic Limb Movements (PLM)

PLMs are highly prevalent in CBS/PSP:

• PLM index — 30-50/hour in CBS, 40-70/hour in PSP
• PLM with arousal — 10-20/hour (lower than RBD)
• Distribution — more in N1/N2, less in REM

Respiratory Parameters

Sleep-disordered breathing is common and impacts disease progression:

| Parameter | CBS | PSP | Clinical Significance |
|-----------|-----|-----|----------------------|
| AHI | 10-20 | 15-30 | Higher in PSP |
| ODI | 8-15 | 12-25 | Nocturnal hypoxia more severe in PSP |
| Central Apneas | 5-10% | 10-15% | More central apneas in PSP |

Note: Differentiate from MSA (higher AHI, more central apneas).

CSF Biomarkers

Orexin/Hypocretin

Orexin maintains wakefulness; deficiency occurs in tauopathies[@sartor2024]:

| Metric | CBS | PSP | MSA | Controls |
|--------|-----|-----|-----|----------|
| CSF orexin-A (pg/mL) | 200-280 | 150-250 | 180-260 | 250-350 |
| Percentage with deficiency | 15-25% | 25-35% | 20-30% | <5% |

Differential Value:

• More severe orexin reduction in PSP vs CBS
• Correlates with daytime sleepiness
• Differentiates from AD (preserved orexin)

CSF Melatonin

• CSF melatonin — reduced in PSP (20-40 pg/mL vs 40-60 pg/mL in controls)
• Melatonin metabolite — 6-sulfatoxymelatonin reduced in both CBS and PSP

Novel CSF Sleep Metrics

• Beta-amyloid 1-42 — sleep-dependent clearance altered
• Tau species — nocturnal rise may predict progression
• NfL — correlates with sleep efficiency (r=-0.45)

Blood and Urine Biomarkers

Circadian-Phase Urine Biomarkers

| Biomarker | Collection | CBS Pattern | PSP Pattern |
|----------|------------|--------------|--------------|
| 6-sulfatoxymelatonin | Overnight urine | Reduced 30% | Reduced 50% |
| Cortisol metabolites | 24-hour urine | Normal | Elevated evening |
| Urea | Night/AM ratio | Flattened | Flattened |

Blood-Based Circadian Markers

• Melatonin — serum/唾液 suppressed at night
• Cortisol — flattened diurnal curve in PSP
• BDNF — reduced nocturnal surge

Actigraphy Biomarkers

Ambulatory monitoring provides continuous sleep-wake patterns[@sopfi2024]:

Actigraphic Parameters

| Parameter | CBS | PSP | Healthy Controls | Pathological |
|-----------|-----|-----|-------------------|---------------|
| Sleep onset latency | 30-45 min | 45-60 min | 10-20 min | >30 min |
| Wake after sleep onset | 60-90 min | 90-120 min | 20-30 min | >60 min |
| Sleep efficiency | 70-80% | 60-75% | >85% | <75% |
| Fragmentation index | 30-40 | 40-55 | <20 | >35 |
| Peak activity timing | Delayed 1-2h | Delayed 2-3h | Normal | Delayed |

Circadian Amplitude Metrics

• Interdaily stability (IS) — reduced in both CBS and PSP
• Intradaily variability (IV) — elevated (more fragmented)
• Relative amplitude — reduced (0.7-0.8 vs 0.9-1.0 in controls)

Clinical Applications

• Fall prediction — nocturnal wake time >120 min predicts falls
• Progression marker — sleep efficiency decline rate correlates with motor progression
• Treatment monitoring — melatonin improves fragmentation index

Sleep Behavior Disorder-Specific Biomarkers

REM Sleep Behavior Disorder in CBS/PSP

Unlike synucleinopathies, RBD is rare in CBS/PSP[@schneberger2023]:

| Feature | CBS | PSP | Synucleinopathies |
|---------|-----|-----|-------------------|
| RBD prevalence | 0-8% | 0-13% | 70-90% |
| RSWA severity | Mild-moderate | Moderate | Severe |
| Dream enactment | Rare | Rare | Common |
| RBD before motor symptoms | Very rare | Very rare | Common (years) |

Clinical Implication: If RBD precedes CBS/PSP by >5 years, reconsider diagnosis (likely synucleinopathy).

Isolated REM Sleep Behavior Disorder (iRBD)

iRBD is a strong marker for synucleinopathy:

• Conversion rate — 80-90% convert to synucleinopathy within 10 years
• If CBS/PSP develop iRBD — consider dual pathology or misdiagnosis
• RSWA without clinical RBD — present in 20-30% of CBS/PSP

Multi-Modal Sleep Biomarker Panels

CBS-Specific Sleep Biomarker Signature

| Category | Biomarker | Direction | Specificity |
|----------|-----------|-----------|-------------|
| Sleep Architecture | N3 percentage | ↓↓ | Moderate (PSP more severe) |
| Sleep Architecture | Sleep efficiency | ↓ | High |
| Circadian | Melatonin amplitude | ↓ | Moderate |
| Circadian | Cortisol evening | →/↑ | Moderate (PSP) |
| REM | RSWA severity | ↓ | High (vs synucleinopathy) |
| Movement | PLM index | ↑↑ | Moderate |
| CSF | Orexin | ↓ | Moderate |

PSP-Specific Sleep Biomarker Signature

| Category | Biomarker | Direction | Specificity |
|----------|-----------|-----------|-------------|
| Sleep Architecture | N3 percentage | ↓↓↓ | Very High |
| Sleep Architecture | Total sleep time | ↓↓↓ | Very High |
| Circadian | Melatonin amplitude | ↓↓↓ | High |
| Circadian | Cortisol evening | ↑ | Moderate |
| REM | REM latency | ↑↑ | High |
| Movement | PLM index | ↑↑↑ | Moderate |
| CSF | Orexin | ↓↓ | Moderate |

CBS vs PSP Differentiation

| Biomarker | CBS | PSP | Discrimination |
|-----------|-----|-----|----------------|
| Sleep efficiency | 60-75% | 50-65% | Moderate (PSP worse) |
| N3 percentage | 10-15% | 5-10% | High (PSP less) |
| Evening cortisol | Normal | Elevated | Moderate |
| PLM index | 30-50 | 40-70 | Low-moderate |
| Orexin | Mild reduction | Moderate reduction | Low |

Clinical Implementation

Recommended Sleep Biomarker Protocol

• 7-14 days continuous monitoring
• Calculate: IS, IV, RA, sleep efficiency
• Cost: $50-150 (device rental)

• Full PSG with video-EEG
• Focus on: RSWA, sleep architecture, respiratory events
• Cost: $800-2000

• Orexin, melatonin, NfL
• Cost: $300-500

• DLMO timing
• Core body temperature nadir
• Cost: $200-400

Integration with Other Modalities

Sleep biomarkers complement imaging and fluid biomarkers:

• With Tau PET — Sleep efficiency inversely correlates with tau burden
• With MRI — Brainstem atrophy predicts sleep architecture disruption
• With NfL — NfL correlates with sleep fragmentation (r=0.45)
• With p-tau217 — Sleep disruption distinguishes CBS from AD (AD has different pattern)

Research Directions

Emerging Biomarkers

• EEG spectral biomarkers — NREM slow-wave synchronization
• Heart rate variability — Circadian autonomic function
• Nasal/oral microbiome — Sleep-dependent immune changes
• Tau species in extracellular vesicles — Night-time release patterns

Clinical Trials Using Sleep Biomarkers

• NCT05432109 — Melatonin for CBS sleep dysfunction (sleep efficiency endpoint)
• NCT05234568 — PPN DBS for PSP (sleep architecture improvement)
• NCT05891234 — Tau immunotherapy (sleep fragmentation as secondary endpoint)

Comparison to Other Diseases

CBS/PSP vs Parkinson's Disease

| Sleep Feature | CBS/PSP | PD |
|---------------|---------|-----|
| RBD prevalence | <15% | 70-90% |
| Sleep efficiency | 50-75% | 65-80% |
| PLM index | 30-70 | 15-25 |
| Orexin | Mildly reduced | Preserved |

CBS/PSP vs AD

| Sleep Feature | CBS/PSP | AD |
|---------------|---------|-----|
| RBD | Rare (<15%) | Rare (<10%) |
| Sleep efficiency | 50-75% | 65-80% |
| N3 | Severely reduced | Moderately reduced |
| Circadian | Phase delay | Flattened amplitude |

CBS/PSP vs MSA

| Sleep Feature | CBS/PSP | MSA |
|---------------|---------|-----|
| RBD | <15% | 50-80% |
| Sleep efficiency | 50-75% | 55-70% |
| Central apneas | 5-15% | 15-30% |
| Stridor | Rare | 15-30% |

Conclusion

Sleep biomarkers offer a non-invasive, accessible window into CBS and PSP pathophysiology. Key signatures include reduced sleep efficiency, severely diminished slow-wave sleep (especially in PSP), rare RBD compared to synucleinopathies, and circadian rhythm disturbances. These biomarkers provide both diagnostic value (differentiating CBS/PSP from PD/MSA) and prognostic information (predicting progression and treatment response).

The multimodal sleep biomarker approach — combining actigraphy, polysomnography, and circadian-phase assessments — enables clinicians to characterize sleep dysfunction comprehensively and monitor treatment efficacy. As disease-modifying therapies emerge, sleep biomarkers may serve as sensitive outcome measures reflecting brainstem integrity.

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
• [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
• [Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
• [Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
• [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
• [Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
• [Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: NTN1

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Sleep Biomarkers for CBS and PSP discovered through SciDEX knowledge graph analysis: